IP Library › Granted Patent US 11,369,674
Granted Patent B2
US 11,369,674 · App. 16/520,113 · Granted Jun 28, 2022

Treatment method utilizing chikungunya virus (CHIKV) virus-like particles (VLPS) comprising the C, E2 and E1 structural proteins

Inventors: Gary J. Nabel (Chestnut Hill, MA); Wataru Akahata (Kensington, MD); Srinivas Rao (Columbia, MD)
Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
A61K39/12C12N7/00C12N7/045A61K2039/5258A61K2039/55566C12N2740/16043C12N2770/36123C12N2770/36134Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,369,674
App. No.
16/520,113
Granted
Jun 28, 2022
Kind
B2
Abstract

The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.

Claims (7)

1. A method for treating or preventing a Chikungunya virus (CHIKV) infection in a subject, comprising administering to the subject a virus-like particle (VLP) comprising CHIKV strain 37997 structural proteins, wherein the CHIKV strain 37997 structural proteins comprise at least CHIKV capsid (C) protein, CHIKV E2 protein, and CHIKV E1 protein, and wherein the VLP does not carry genetic information encoding the VLP proteins.

2. The method of claim 1 , wherein the one or more structural proteins are selected from the group consisting of CHIKV capsid (C) protein, CHIKV E3 protein, CHIKV E2 protein, CHIKV 6K protein, and CHIKV E1 protein.

3. The method of claim 1 , wherein the VLP comprises CHIKV envelope proteins E3, E2, 6K and E1.

4. The method of claim 1 , wherein the VLP comprises CHIKV envelope proteins E1 and E2, and CHIKV capsid protein.

5. The method of claim 1 , wherein the VLP comprises CHIKV envelope proteins E1 and E2.

6. The method of claim 1 , comprising preventing the CHIKV infection.

7. The method of claim 1 , wherein the subject is at risk of the CHIKV infection.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2019
From: NABEL, GARY J.; AKAHATA, WATARU; RAO, SRINIVAS S.
To: THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES
Reel/Frame 049915/0160 →
Continuity (5)
Division 15145483 · May 3, 2016
Division 13131287
Provisional Application 61201118 · Dec 5, 2008
Provisional Application 61118206 · Nov 26, 2008
Related Publication 20200085938A1 · Mar 19, 2020